Aralez Pharmaceuticals Inc. (ARLZ) Receives “Positive” Rating from Guggenheim
Separately, Chardan Capital reissued a buy rating and issued a $10.00 price target on shares of Aralez Pharmaceuticals in a report on Friday, September 16th.
Aralez Pharmaceuticals (NASDAQ:ARLZ) traded down 0.1895% during midday trading on Tuesday, reaching $5.3199. 313,023 shares of the company traded hands. The firm has a 50-day moving average of $5.29 and a 200-day moving average of $4.15. The stock’s market capitalization is $347.08 million. Aralez Pharmaceuticals has a 1-year low of $3.10 and a 1-year high of $8.59.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.08. The business earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. Aralez Pharmaceuticals’s revenue was up 142.3% compared to the same quarter last year. On average, analysts predict that Aralez Pharmaceuticals will post ($1.05) earnings per share for the current year.
In other news, Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total value of $873,000.00. Following the completion of the sale, the director now directly owns 669,094 shares in the company, valued at $3,894,127.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.77% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. California Public Employees Retirement System boosted its stake in Aralez Pharmaceuticals by 10.0% in the second quarter. California Public Employees Retirement System now owns 105,867 shares of the company’s stock worth $349,000 after buying an additional 9,667 shares during the period. Alps Advisors Inc. boosted its stake in Aralez Pharmaceuticals by 24.9% in the second quarter. Alps Advisors Inc. now owns 89,850 shares of the company’s stock worth $297,000 after buying an additional 17,920 shares during the period. Janus Capital Management LLC boosted its stake in Aralez Pharmaceuticals by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,603,757 shares of the company’s stock worth $5,292,000 after buying an additional 20,623 shares during the period. FNY Managed Accounts LLC boosted its stake in Aralez Pharmaceuticals by 73.3% in the second quarter. FNY Managed Accounts LLC now owns 52,000 shares of the company’s stock worth $172,000 after buying an additional 22,000 shares during the period. Finally, Bank of Montreal Can acquired a new stake in Aralez Pharmaceuticals during the second quarter worth approximately $100,000. Institutional investors and hedge funds own 49.63% of the company’s stock.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Stock Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.